docetaxel anhydrous has been researched along with sl 327 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (sl 327) | Trials (sl 327) | Recent Studies (post-2010) (sl 327) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 88 | 0 | 40 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | sl 327 (IC50) |
|---|---|---|---|
| epidermal growth factor receptor isoform a precursor | Homo sapiens (human) | 100 | |
| Transcription factor AP-1 | Homo sapiens (human) | 2.03 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Wang, W; Zhao, L; Zhou, J | 1 |
1 other study(ies) available for docetaxel anhydrous and sl 327
| Article | Year |
|---|---|
Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Topics: Aminoacetonitrile; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Humans; Indoles; Mice, Nude; Pyrroles; Sunitinib; Taxoids; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2017 |